<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265629</url>
  </required_header>
  <id_info>
    <org_study_id>BEP-4405</org_study_id>
    <nct_id>NCT00265629</nct_id>
  </id_info>
  <brief_title>RF Ablation of Atrial Fibrillation</brief_title>
  <official_title>A Clinical Investigation of Radiofrequency Ablation for the Treatment of Atrial Fibrillation Using the High Density Mesh Bard Ablation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an early feasibility trial designed to demonstrate whether a new ablation device can&#xD;
      be used safely and effectively in treating atrial fibrillation.&#xD;
&#xD;
      This study is a prospective, nonrandomized, single-arm, multi-center trial to be conducted at&#xD;
      a single study site&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended to evaluate the safety and preliminary effectiveness of the RFMesh BAS&#xD;
      for electrophysiological mapping and radiofrequency ablation in the region of the ostium of a&#xD;
      targeted pulmonary vein in the treatment of drug refractory paroxysmal atrial fibrillation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the safety of the HDMA when used to map &amp; ablate patients with AF, by assessing MCs at 7-days &amp; 30 days post-procedure &amp; assessing the occurrence of pulmonary vein stenosis at 3 &amp; 12 months post-procedure.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the preliminary effectiveness of the HDMA when used to map and ablate patients with paroxysmal AF, by assessing APS &amp; the freedom from recurrence of symptomatic AF at 3, 6 &amp; 12 months post- procedure.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RF ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RF catheter ablation</intervention_name>
    <description>RF ablation using mesh device</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who are between 18 &amp; 85 years of age.&#xD;
&#xD;
          2. Patients with a minimum of 2 episodes of symptomatic PAF within the last 6 months&#xD;
             prior to baseline evaluation. At least one of these episodes must have been&#xD;
             documented. Documentation may include electrocardiogram (ECG), trans telephonic&#xD;
             monitoring (TTM), Holter monitoring (HM), or telemetry strip. Additional PAF episodes&#xD;
             (i.e., verbal accounts from the patient) will be documented in the patient's study&#xD;
             record.&#xD;
&#xD;
          3. Patients who have failed at least 1 class I or class III anti-arrhythmic medication&#xD;
             regimen.&#xD;
&#xD;
          4. Patients with the ability to understand the requirements of the study, who have&#xD;
             provided written informed consent and agreed to the study restrictions and to return&#xD;
             for the required follow-up assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any previous ablation of the left atrium (surgical or catheter based).&#xD;
&#xD;
          2. Permanent or persistent atrial fibrillation.&#xD;
&#xD;
          3. Recent myocardial infarction within 2 months&#xD;
&#xD;
          4. Currently unstable angina.&#xD;
&#xD;
          5. Any cardiac surgery during the previous 3 months.&#xD;
&#xD;
          6. Currently documented intracardiac thrombus by transesophageal echocardiography (TEE).&#xD;
&#xD;
          7. A left atrium &gt; 50mm in major dimension.&#xD;
&#xD;
          8. A common ostium larger than 25 mm in major axis or any individual pulmonary vein&#xD;
             larger than 25 mm in major axis.&#xD;
&#xD;
          9. Permanent leads in or through the right atrium.&#xD;
&#xD;
         10. Clinically significant valvular heart disease or a replacement heart valve.&#xD;
&#xD;
         11. Congestive heart failure (NYHA classification III or IV).&#xD;
&#xD;
         12. An ejection fraction &lt;35%.&#xD;
&#xD;
         13. A contraindication to warfarin.&#xD;
&#xD;
         14. A contraindication to transseptal procedure.&#xD;
&#xD;
         15. Any cerebral ischemic event, including any transient ischemic attack (TIA), in the&#xD;
             preceding 6 months.&#xD;
&#xD;
         16. Any known bleeding disorder.&#xD;
&#xD;
         17. Women who are known to be pregnant or nursing.&#xD;
&#xD;
         18. Uncontrolled hyperthyroidism.&#xD;
&#xD;
         19. Patients currently enrolled in any other clinical investigation.&#xD;
&#xD;
         20. Any other significant uncontrolled or unstable medical condition.&#xD;
&#xD;
         21. A life expectancy of less than one year.&#xD;
&#xD;
         22. Currently taking amiodarone or have taken amiodarone within 4 months prior to baseline&#xD;
             evaluation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>David Haines, MD</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 14, 2005</study_first_submitted>
  <study_first_submitted_qc>December 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2005</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

